As per the latest report of DelveInsight the estimated diagnosed NASH prevalence will reach 18 Million by 2027 for 7MM’s (US, Germany, France, Spain, Italy, UK and Japan). Nonalcoholic Steatohepatitis (NASH) is a type of NAFLD (Nonalcoholic Fatty Liver Disease) characterized by inflammation and excessive buildup of fat in the liver strongly associated with insulin resistance, central obesity, Type II diabetes mellitus etc. NASH is widely being seen for the major cause of various liver transplants worldwide.
According to “Nonalcoholic Steatohepatitis (NASH) – Market Insights, Epidemiology and Market Forecast – 2027”, prevalence of diagnosed NASH is estimated to have a CAGR of 2.82% for 7MM’s. There are no approved therapies for the treatment of NASH currently, only off-label drugs are available for the management of the disease. However, a large number of drugs are in the pipeline out of which Obeticholic acid (Intercept Pharmaceuticals) and Elafibranor (GenfitPharma) are estimated to have the highest sales due to early mover advantage as compared to others which are launching in the NASH market before 2027.
Due to the expected launch of highly promising drugs that are currently in the pipeline of large pharmaceutical companies NASH market will reach up to USD 49 Billion in 2027 as per the companies report. Among the 7MM’s US will have the Lion’s share in the market size of NASH due to the maximum prevalence according to the statistical reports.
The latest report has covered detailed information about all the possible movers and barriers in the market of NASH for the complete market scenario in the upcoming future in the 7 Major Markets. It provides detailed insight about the epidemiology forecasts, therapeutic market revenue and upcoming therapeutic advancements in the NASH domain. There will be an estimated uptake of 8 potential therapies during our forecast period from 2015-2027. With the approval of Obeticholic acid (Intercept Pharmaceuticals) and Elafibranor (GenfitPharma), Selonsertib (Gilead Biosciences), Cenicriviroc (Allergan- Tobira), etc, the NASH domain will experience a revolution both in terms of market size and treatment approach.
Reasons to buy:
- The report will help in developing business strategies by understanding trends shaping and driving the Nonalcoholic Steatohepatitis market.
- To understand the future market competition in the NASH market and Insight reviews of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for NASH in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
- Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Phone: +1 646 845 9349, +44 208 133 9349